Literature DB >> 26895982

Drug Transport by the Blood-Aqueous Humor Barrier of the Eye.

Jonghwa Lee1, Ryan M Pelis2.   

Abstract

The ocular barriers (cornea, blood-retinal barrier, and blood-aqueous humor barrier) make treating eye diseases with therapeutic drugs challenging. The tight capillary endothelium of the iris and the ciliary body epithelium form the blood-aqueous humor barrier. The iris and ciliary body (iris-ciliary body) express a variety of drug transporters in the ATP-binding cassette and solute carrier (SLC) families. ATP-binding cassette family drug transporters that are present in the iris-ciliary body include P-glycoprotein, breast cancer resistance protein, and several multidrug resistance-associated proteins. SLC family drug transporters that are present in the iris-ciliary body include organic anion transporters, organic anion transporting polypeptides, bile acid transporters (apical sodium-dependent bile salt transporter and sodium taurocholate cotransporter), organic cation transporters (novel organic cation transporter and multidrug and toxin extrusion transporter) and peptide transporters. Freshly dissected iris-ciliary body preparations actively accumulate a variety of substrates of SLC drug transporters that are expressed in the tissue. The ciliary body in vitro supports active transport in the aqueous humor-to-blood direction of several substrates of organic anion transporters and multidrug resistance-associated proteins, consistent with the subcellular localization of these transporters in the ciliary body epithelium. In vivo data suggest that drug transporters in the iris-ciliary body reduce the permeation of drugs in the direction of blood-to-aqueous humor, thereby reducing ocular drug bioavailability, and are also involved in active drug elimination from the aqueous humor. An understanding of the influence on pharmacokinetics of drug transporters in the blood-aqueous humor barrier should help improve drug delivery and efficacy in the eye.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26895982     DOI: 10.1124/dmd.116.069369

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

Review 1.  Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.

Authors:  Abhirup Mandal; Rohit Bisht; Ilva D Rupenthal; Ashim K Mitra
Journal:  J Control Release       Date:  2017-01-11       Impact factor: 9.776

Review 2.  Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Authors:  Sascha C T Nicklisch; Amro Hamdoun
Journal:  FEBS Lett       Date:  2020-12-09       Impact factor: 4.124

Review 3.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

4.  Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: Retrospective comparative Analysis of an interventional case series.

Authors:  Kang Yeun Pak; Beom Seok Choi; Sung Who Park; Ik Soo Byon; Ji Eun Lee
Journal:  Indian J Ophthalmol       Date:  2017-06       Impact factor: 1.848

Review 5.  Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.

Authors:  Ivan Seah; Xinxin Zhao; Qianyu Lin; Zengping Liu; Steven Zheng Zhe Su; Yew Sen Yuen; Walter Hunziker; Gopal Lingam; Xian Jun Loh; Xinyi Su
Journal:  Eye (Lond)       Date:  2020-01-30       Impact factor: 3.775

Review 6.  Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives.

Authors:  Laure-Alix Clerbaux; Alicia Paini; Annie Lumen; Hanan Osman-Ponchet; Andrew P Worth; Olivier Fardel
Journal:  Environ Int       Date:  2019-03-08       Impact factor: 9.621

7.  Efficacy of systemic administration of riboflavin on a rabbit model of corneal alkali burn.

Authors:  Maksym Żuk; Ekaterina Lobashova; Olga Żuk; Sławomir Wierzba
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

Review 8.  Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.

Authors:  Jose Navarro-Partida; Carlos Rodrigo Castro-Castaneda; Francisco J Santa Cruz-Pavlovich; Luis Abraham Aceves-Franco; Tomer Ori Guy; Arturo Santos
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

Review 9.  Lipid Nanoparticles for the Posterior Eye Segment.

Authors:  Lorena Bonilla; Marta Espina; Patricia Severino; Amanda Cano; Miren Ettcheto; Antoni Camins; Maria Luisa García; Eliana B Souto; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2021-12-31       Impact factor: 6.321

Review 10.  Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances.

Authors:  Shery Jacob; Anroop B Nair; Jigar Shah; Sumeet Gupta; Sai H S Boddu; Nagaraja Sreeharsha; Alex Joseph; Pottathil Shinu; Mohamed A Morsy
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.